James Wheless
Overview
Explore the profile of James Wheless including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wheless J, Wechsler R, Penovich P, Segal E, Chez M, Coppola A, et al.
Epilepsy Behav
. 2023 Aug;
147:109369.
PMID: 37619459
Objective: To assess the effectiveness and safety/tolerability of perampanel (PER) in people with epilepsy (PWE) treated in everyday clinical practice for focal and generalized seizures, both in the total cohort...
12.
Safety evaluation of perampanel as monotherapy or first adjunctive therapy in patients with epilepsy
Wheless J, Chourasia N
Expert Opin Drug Saf
. 2022 Oct;
21(10):1239-1247.
PMID: 36263757
Introduction: There is a need for anti-seizure medications (ASMs) that are well tolerated and effective as monotherapy or first adjunctive therapy to reduce the need for adjunctive ASMs to treat...
13.
Segal E, Wheless J, Moretz K, Penovich P, Patten A, Malhotra M
Seizure
. 2022 Apr;
98:87-94.
PMID: 35453064
Purpose: Report final data from adolescent (12-<18 years) and adult (≥18 years) patients from PROVE (NCT03208660), a multicenter, retrospective, non-interventional, Phase IV study to assess retention, efficacy, safety, and dosing...
14.
Wheless J, Peters J, Misra S, Becker D, Rabinowicz A, Sirven J, et al.
Epilepsy Behav
. 2022 Jan;
128:108550.
PMID: 35063372
No abstract available.
15.
Segal E, Moretz K, Wheless J, Penovich P, Lancman M, Patten A, et al.
J Child Neurol
. 2022 Jan;
37(4):256-267.
PMID: 34994582
PROVE is a retrospective, phase IV study assessing retention, dosing, efficacy, and safety of perampanel when administered to patients during routine clinical care. We report an interim analysis of preadolescent...
16.
Thiele E, Bebin E, Filloux F, Kwan P, Loftus R, Sahebkar F, et al.
Epilepsia
. 2021 Dec;
63(2):426-439.
PMID: 34957550
Objective: To evaluate the long-term safety and efficacy of add-on cannabidiol (CBD) in patients with seizures associated with tuberous sclerosis complex (TSC) in the open-label extension (OLE) of the randomized,...
17.
Wechsler R, Wheless J, Zafar M, Huesmann G, Lancman M, Segal E, et al.
Epilepsia Open
. 2021 Dec;
7(2):293-305.
PMID: 34942053
Objective: To assess retention, dosing, efficacy, and safety of perampanel in a large cohort of patients with epilepsy during routine clinical care. Methods: PROVE was a retrospective, non-interventional Phase IV...
18.
Coursimault J, Guerrot A, Morrow M, Schramm C, Zamora F, Shanmugham A, et al.
Hum Genet
. 2021 Nov;
141(1):65-80.
PMID: 34748075
Pathogenic variants of the myelin transcription factor-1 like (MYT1L) gene include heterozygous missense, truncating variants and 2p25.3 microdeletions and cause a syndromic neurodevelopmental disorder (OMIM#616,521). Despite enrichment in de novo...
19.
Vazquez B, Wheless J, Desai J, Rabinowicz A, Carrazana E
Epilepsy Behav
. 2021 Mar;
118:107898.
PMID: 33752044
Intranasal formulations are commonly used for drug delivery, and the literature has shown that seasonal allergies do not affect nasal administration of some agents. Diazepam nasal spray (Valtoco®) is a...
20.
Wheless J, Wechsler R, Lancman M, Aboumatar S, Patten A, Malhotra M
Epilepsia Open
. 2021 Mar;
6(1):79-89.
PMID: 33681651
Objective: To assess the retention rate, efficacy, safety, and dosing of perampanel administered to patients with epilepsy during routine clinical care in the retrospective phase IV, PROVE Study (NCT03208660). Methods:...